JP2016515537A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515537A5
JP2016515537A5 JP2016503457A JP2016503457A JP2016515537A5 JP 2016515537 A5 JP2016515537 A5 JP 2016515537A5 JP 2016503457 A JP2016503457 A JP 2016503457A JP 2016503457 A JP2016503457 A JP 2016503457A JP 2016515537 A5 JP2016515537 A5 JP 2016515537A5
Authority
JP
Japan
Prior art keywords
kinase
cancer
disease
receptor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515537A (ja
JP6553589B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/030760 external-priority patent/WO2014145909A2/en
Publication of JP2016515537A publication Critical patent/JP2016515537A/ja
Publication of JP2016515537A5 publication Critical patent/JP2016515537A5/ja
Application granted granted Critical
Publication of JP6553589B2 publication Critical patent/JP6553589B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503457A 2013-03-15 2014-03-17 ピリミド−ジアゼピノン化合物および障害の治療方法 Active JP6553589B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361802075P 2013-03-15 2013-03-15
US61/802,075 2013-03-15
PCT/US2014/030760 WO2014145909A2 (en) 2013-03-15 2014-03-17 Pyrimido-diazepinone compounds and methods of treating disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018111642A Division JP6553772B2 (ja) 2013-03-15 2018-06-12 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2019125063A Division JP2019206534A (ja) 2013-03-15 2019-07-04 ピリミド−ジアゼピノン化合物および障害の治療方法

Publications (3)

Publication Number Publication Date
JP2016515537A JP2016515537A (ja) 2016-05-30
JP2016515537A5 true JP2016515537A5 (cg-RX-API-DMAC7.html) 2019-03-28
JP6553589B2 JP6553589B2 (ja) 2019-07-31

Family

ID=51538565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503457A Active JP6553589B2 (ja) 2013-03-15 2014-03-17 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2018111642A Active JP6553772B2 (ja) 2013-03-15 2018-06-12 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2019125063A Pending JP2019206534A (ja) 2013-03-15 2019-07-04 ピリミド−ジアゼピノン化合物および障害の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018111642A Active JP6553772B2 (ja) 2013-03-15 2018-06-12 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2019125063A Pending JP2019206534A (ja) 2013-03-15 2019-07-04 ピリミド−ジアゼピノン化合物および障害の治療方法

Country Status (5)

Country Link
US (4) US9676792B2 (cg-RX-API-DMAC7.html)
EP (4) EP2970317A4 (cg-RX-API-DMAC7.html)
JP (3) JP6553589B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902599C (cg-RX-API-DMAC7.html)
WO (1) WO2014145909A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112017003651A2 (pt) * 2014-09-02 2017-12-05 Pf Medicament derivados de isoquinolinona úteis no tratamento de câncer
CN104803914B (zh) * 2015-03-05 2017-11-14 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
EP3307069B1 (en) * 2015-06-10 2021-08-04 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2019512459A (ja) * 2016-03-04 2019-05-16 アンホイ ニュー スター ファーマシューティカル デベロップメント カンパニー,リミテッド 7員環化合物、その調製方法、その医薬組成物、およびその使用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
EA038531B1 (ru) * 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
CA3040173A1 (en) * 2016-10-18 2018-04-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Fgfr4インヒビターおよび胆汁酸捕捉薬の組合せ
SG11201908234WA (en) * 2017-02-24 2019-10-30 Daegu Gyeongbuk Medical Innovation Found Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
US10298137B2 (en) * 2017-03-10 2019-05-21 Semiconductor Components Industries, Llc Advanced frequency reduction of quasi-resonant converters
AU2018392805A1 (en) 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
US20210333285A1 (en) * 2018-04-13 2021-10-28 The Regents Of The University Of California Detection of phosphokinase signatures
JP7201800B2 (ja) * 2018-09-30 2023-01-10 メッドシャイン ディスカバリー インコーポレイテッド Flt3およびaxlの阻害剤としての3,9-ジアザスピロ[5,5]ウンデカン系化合物
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN109824678B (zh) * 2019-03-20 2020-06-19 浙江大学 一种氮杂卓吲哚类生物碱及制备和抗疟疾用途
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US12365696B2 (en) 2019-05-10 2025-07-22 Dana-Farber Cancer Institute, Inc. Small-molecule focal adhesion kinase (FAK) inhibitors
AU2020300619A1 (en) * 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20220280530A1 (en) * 2019-08-08 2022-09-08 Anhui Newstar Pharmaceutical Development Co., Ltd. Prevention or treatment of diseases and disorders associated with tissue damage
KR102498531B1 (ko) * 2020-06-29 2023-02-13 한국과학기술연구원 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체
WO2022061019A1 (en) * 2020-09-16 2022-03-24 Collaborations Pharmaceuticals, Inc. The antiviral drug tilorone is a potent and selective inhibitor of acetylcholinesterase
EP4229061A4 (en) * 2020-10-14 2024-09-25 Ranok Therapeutics (Hangzhou) Co. Ltd. METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION
EP4238974A4 (en) * 2020-10-28 2024-10-23 Adlai Nortye Biopharma Co., Ltd. HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
US12577253B2 (en) 2021-02-08 2026-03-17 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 5,6-dihydrothieno[3,4-h]quinazoline compound
TW202321244A (zh) * 2021-07-26 2023-06-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
WO2023055827A1 (en) * 2021-09-30 2023-04-06 Crinetics Pharmaceuticals, Inc. Parathyroid hormone (pth) receptor antagonists and uses thereof
CN114478539B (zh) * 2022-02-09 2024-02-02 中国人民解放军海军军医大学 一种新型dclk1抑制剂及其制备方法和应用
CN115877004B (zh) * 2022-08-09 2024-12-20 重庆大学 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用
CN116173040B (zh) * 2022-08-23 2025-05-23 杭州天玑济世生物科技有限公司 Xmd17109作为arih1激动剂的用途
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
CN121154824A (zh) * 2025-11-19 2025-12-19 安徽省立医院(中国科学技术大学附属第一医院) Nuak1作为生物标志物在骨质疏松临床诊断和预防中的应用及其试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES

Similar Documents

Publication Publication Date Title
JP2018168169A5 (cg-RX-API-DMAC7.html)
CN113474340B (zh) 作为ras抑制剂的新型异吲哚啉酮取代的吲哚和衍生物
ES2734713T3 (es) Moduladores Cot y métodos de utilización de los mismos
ES2921257T3 (es) Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
RS64167B1 (sr) Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori
RS66557B1 (sr) [1,3]diazino[5,4-d]pirimidini kao her2 inhibitori
BR112021016132A2 (pt) Novo derivado de pirido[3,4-d]pirimidin-8-ona tendo atividade inibitória da proteína quinase e composição farmacêutica para prevenir, aliviar ou tratar o câncer, que o compreende
US10266537B2 (en) 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
ECSP19042688A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
ES2318158T3 (es) Derivdos de diaril urea utiles para el tratamiento de enfermedades dependientes de la proteina quinasa.
WO2013143466A1 (zh) 作为欧若拉激酶抑制剂的取代嘧啶衍生物
JP6896755B2 (ja) エクソン20挿入変異型egfr選択的阻害剤
WO2018108704A1 (en) New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
CL2017000420A1 (es) Compuestos diaza-y triaza-triciclicos sustituidos con ciclohexil-etilo como antagonistas de indol-amina-2,3-dioxigenasa (ido) para el tratamiento de cáncer.
JP2017514907A5 (cg-RX-API-DMAC7.html)
CN110546150B (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
CN112789279B (zh) 含三并环类衍生物抑制剂、其制备方法和应用
BRPI0922801A2 (pt) compostos
WO2022167457A1 (en) Gpr84 antagonists and uses thereof
US9845320B2 (en) Benzothiazole or benzoxazole compounds as sumo activators
TW200804364A (en) New compounds
JPWO2019045036A1 (ja) エクソン18及び/又はエクソン21変異型egfr選択的阻害剤
MX2016013968A (es) Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
CL2016001739A1 (es) Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands